GO
Loading...

Pharmaceuticals

More

  • March 13- Generic drugmaker Par Pharmaceutical Holdings Inc, owned by private equity firm TPG Capital, filed with U.S. regulators for an initial public offering of common stock. The major underwriters include J.P. Morgan, Goldman Sachs& Co, Citigroup and Morgan Stanley, Par Pharma said in a filing to the U. S Securities and Exchange Commission on Friday.

  • Par Pharmaceutical files for IPO Friday, 13 Mar 2015 | 6:47 AM ET

    March 13- Generic drugmaker Par Pharmaceutical Holdings Inc, owned by private equity firm TPG Capital, filed with U.S. regulators for an initial public offering of common stock. The major underwriters include J.P. Morgan, Goldman Sachs& Co, Citigroup and Morgan Stanley, Par Pharma said in a filing to the U. S Securities and Exchange Commission on Friday.

  • NEW YORK, March 12- Johnson& Johnson sued rival drugmaker GlaxoSmithKline PLC on Thursday, alleging that Glaxo is trying to unlawfully grab market share with false advertising at the start of spring allergy season in the United States. Two Johnson& Johnson units, McNeil-PPC Inc and McNeil Consumer Healthcare, filed the lawsuit in U.S. District Court in Manhattan.

  • March 12- Endo International Plc's $11 billion offer this week for Salix Pharmaceuticals Ltd, an effort to trump an agreed $10 billion bid from Valeant Pharmaceutical Inc, illustrates CEO Rajiv De Silva's plan to be seen as not just a protege of Valeant chief Mike Pearson, but as a challenger. If successful, buying Raleigh, North Carolina- based Salix would combine...

  • WASHINGTON, March 11- The entry of copycat biotech drugs into the U.S. market could cut prices of expensive medications by 40 percent to 50 percent, depending on the level of competition among drugmakers, a top executive at CVS Health Corp told Reuters. CVS is one of the largest U.S. pharmacy benefit managers and, along with rival Express Scripts, has put...

  • In a letter released on Wednesday, the organization urged Health and Human Services Secretary Sylvia Burwell to withdraw the proposal, saying pharmaceutical companies could "sell more drugs by making them seem safer than FDA has judged them to be." The FDA said it would allow distribution of new information in medical journals showing that the severity or...

  • Can Amazon-like reviews work for prescriptions? Wednesday, 11 Mar 2015 | 9:00 AM ET
    Pills

    HealthTap is out to let consumers assess prescription drugs the same way they search for clothes, cars and electronics. It's the five-star review.

  • *100 job roles to move to Singapore. SINGAPORE/ LONDON, March 11- Drugmaker GlaxoSmithKline will establish a new headquarters for Asia in Singapore to make quicker decisions for the region, a move that follows a recent rocky ride in China due to a damaging bribery scandal. GSK has over 700 office-based employees in Singapore and expects an additional 100 roles to...

  • March 11- Drugmaker GlaxoSmithKline said on Wednesday it was establishing a new global headquarters for Asia in Singapore, strengthening its presence in the city-state. Chief Executive Andrew Witty has made emerging markets a priority for GSK since taking over in 2008, but the drugmaker has had a rocky ride recently due to a damaging bribery scandal in China.

  • Game changer for health research   Tuesday, 10 Mar 2015 | 10:29 AM ET
    Game changer for health research

    Dr. Kathryn Schmitz, Professor of Epidemiology at University of Pennsylvania, speaks about a new app, "Share the Journey", which is said to track issues related to breast cancer treatment.

  • US specialty drug spending trends in 2015   Tuesday, 10 Mar 2015 | 7:05 AM ET
    US specialty drug spending trends in 2015: CEO

    Our goal is to offer the most choice at the lowest price, says Dr. Steve Miller, Express Scripts CMO, discussing what's behind the rising costs of specialty medications and how drugmakers plan to keep costs down.

  • Prescription drug prices rising: Report   Tuesday, 10 Mar 2015 | 7:04 AM ET
    Prescription drug prices rising: Report

    CNBC's Meg Tirrell has the details on a report from Express Scripts which shows prices on some prescription drugs are soaring.

  • Ackman's $20 billion Pershing Square Capital Management began building up the 5 percent stake in the Canadian drug maker this year, only months after his vocal effort to help Valeant buy Botox-maker Allergan failed. His Pershing Square has notched big wins at railway Canadian Pacific and shopping mall operator General Growth Properties, and also made money...

  • LONDON, March 6- Drugmaker GlaxoSmithKline, which was fined 3 billion yuan in China last year for bribery, is dismissing 110 employees in the country for misconduct, people familiar with the matter said on Friday. We also engaged an independent legal firm and external consultancies to review our operations in China, "GSK said. The company's annual report,...

  • *Zarxio from Novartis generics unit Sandoz approved by FDA. *Copy of Amgen's white cell-boosting medicine Neupogen. The move had been expected after Zarxio, which is made by Novartis' generics unit Sandoz, won unanimous backing from an FDA panel in January.

  • Bubble trouble in biotech?   Friday, 6 Mar 2015 | 7:54 AM ET
    Bubble trouble in biotech?

    Jason Kolbert, Maxim Group, provides perspective on big M&A deals in the biotech space.

  • March 6- Lower-cost versions of biological drugs, known as biosimilars, are taking aim at some of the world's biggest-selling medicines. Unlike chemical compounds, such as aspirin or statins, these biotech products are made of hormones, antibodies and other proteins. DIFFERENT REGULATORY PATHWAYS Biosimilars are already sold in Europe, Japan and other parts...

  • *FDA set to decide on approval of Novartis' Zarxio. LONDON/ LOS ANGELES, March 6- A revolution is brewing in healthcare with lower-cost copies of complex biotech drugs finally set to reach the United States, nine years after so-called biosimilars were launched in Europe. The first approval for a biosimilar in the United States is expected imminently- Zarxio,...

  • Did AbbVie overpay for Pharmacyclics?   Thursday, 5 Mar 2015 | 7:47 PM ET
    Did Abbie overpay for Pharmacyclics?

    Raghuram Selvaraju, managing director, Healthcare equity research at MLV & Co, discusses whether AbbVie's acquisition of Pharmacyclics for about $21 billion is a good move.

  • How will Pharmacyclics complement AbbVie?   Thursday, 5 Mar 2015 | 5:23 PM ET
    How will Pharmacyclics complement AbbVie

    Sachin Shah, merger arbitrage strategist at Albert Fried and Company, discusses why AbbVie's decision to buy Pharmacyclics for about $21 billion is a "longer-dated" move.